Immunomonitoring Reveals Interruption of Anergy After Vaccination in a Case of Type-2-Papillary Renal Cell Carcinoma

Clavijo-Salomon, Maria Alejandra; Bergami-Santos, Patrícia Cruz; Barbuto, José Alexandre Marzagão

doi:10.2217/imt-2016-0145

Cited by 3 publications

(2 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Yet, in another paper we described a patient with type 2-papillary renal cell carcinoma, whose mo-DC also presented functional biases. Though after the tumor was surgically removed, the patient's mo-DC already regained some activity, their T lymphocyte-stimulating activity reached healthy controls' levels only after the patient was submitted to treatment with a dendritic cell-based cancer vaccine (200).…”

Section: Mo-dc As a “Window” To Immune System Evaluation In Cancer Pamentioning

confidence: 99%

Human Dendritic Cells: Their Heterogeneity and Clinical Application Potential in Cancer Immunotherapy

et al. 2019

View full text Add to dashboard Cite

Dendritic cells (DC) are professional antigen presenting cells, uniquely able to induce naïve T cell activation and effector differentiation. They are, likewise, involved in the induction and maintenance of immune tolerance in homeostatic conditions. Their phenotypic and functional heterogeneity points to their great plasticity and ability to modulate, according to their microenvironment, the acquired immune response and, at the same time, makes their precise classification complex and frequently subject to reviews and improvement. This review will present general aspects of the DC physiology and classification and will address their potential and actual uses in the management of human disease, more specifically cancer, as therapeutic and monitoring tools. New combination treatments with the participation of DC will be also discussed.

show abstract

Section: Mo-dc As a “Window” To Immune System Evaluation In Cancer Pamentioning

confidence: 99%

Human Dendritic Cells: Their Heterogeneity and Clinical Application Potential in Cancer Immunotherapy

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Discovering the tumor, host, or environmental features that optimize the response to immune therapy will be the next major breakthrough in advancing immune treatments for this disease. Early indicators suggest that T cell exhaustion and anergy in tumors is not permanent 62 . Consistent with major themes for RCC biology, mTOR and HIF1 are key mediators of immune fate decisions for both CD4 and CD8 T cells 63 , and both PD-1 and CTLA4 checkpoints can potently suppress T cell metabolism to impair effector function 64 .…”

Section: Metabolism Environment and Obesity/inflammationmentioning

confidence: 99%

Metabolic Pathways in Kidney Cancer: Current Therapies and Future Directions

Rathmell

Linehan

2018

JCO

View full text Add to dashboard Cite

Background Renal cell carcinoma (RCC) has become known as a metabolic disease, owing to the diverse array of metabolic defects and perturbations that occur as a result of the unique genetics that can drive these tumors. Recent attention to this feature of RCCs has fueled interest in targeting metabolism as a therapeutic strategy. Methods We conducted a literature search to develop themes around discrete pathways or processes of cellular metabolism, provide a framework for understanding emerging therapeutic strategies, and consider future interventions. Results Defects occur in metabolic pathways ranging from glycolysis to mitochondrial function and affect not only the tumor cell functionality, but also the local environment. We identified opportunities for therapeutic intervention associated with each pathway. Conclusion The metabolism of RCC cells presents a special environment of tumor susceptibilities, with opportunities for novel imaging applications and treatment paradigms that are being tested in monotherapy or as adjuncts to targeted or immune-based strategies.

show abstract

Bioinformatics profiling integrating a four immune-related long non-coding RNAs signature as a prognostic model for papillary renal cell carcinoma

Liu

Gou

Wei

et al. 2020

Aging

View full text Add to dashboard Cite

Background: Papillary renal cell carcinoma (pRCC) was the 2 nd most common subtype, accounting for approximately 15% incidence of renal cell carcinoma (RCC). Immune related long non-coding RNAs (IR-lncRs) plentiful in immune cells and immune microenvironment (IME) are potential in evaluating prognosis and assessing the effects of immunotherapy. A completed and meaningful IR-lncRs analysis based on abundant pRCC gene samples from The Cancer Genome Atlas (TCGA) will provide insight in this field. Results: 17 IR-lncRs were selected by Pearson correlation analysis of immune score and the lncRNA expression level, and 5 sIRlncRs were significantly correlated with the OS of pRCC patients. 4 sIRlncRs (AP001267.3, AC026471.3, SNHG16 and ADAMTS9-AS1) with the most remarkable prognostic values were identified to establish the IRRS model and the OS of the low-risk group was longer than that in the high-risk group. The IRRS was certified as an independent prognosis factor and correlated with the OS. The high-risk group and low-risk group showed significantly different distributions and immune status through PCA and GSEA. In addition, we further found the expression levels of SNHG16 was remarkably enhanced in female patients with more advanced T-stages, but ADAMTS9-AS1 showed the opposite results. Conclusion: The IRRS model based on the identified 4 sIRlncRs showed the significant values on forecasting prognoses of pRCC patients, with the longer OS in the low-risk group. Methods: We integrated the expression profiles of LncRNA and overall survival (OS) in the 322 pRCC patients based on the TCGA dataset. The immune scores calculated on account of the expression level of immune-related genes were used to verify the most relevant IR-lncRs. Survival-related IR-lncRs (sIRlncRs) were estimated by COX regression analysis in pRCC patients. The high-risk group and low-risk group were identified by the median immune-related risk score (IRRS) model established by the screened sIRlncRs. Functional annotation was displayed by gene set enrichment analysis (GSEA) and principal component analysis (PCA), and the immune composition and purity of the tumor were evaluated through microenvironment cell count records. The expression levels of sIRlncRs of pRCC samples were verified by real-time quantitative PCR.

show abstract

Immunomonitoring Reveals Interruption of Anergy After Vaccination in a Case of Type-2-Papillary Renal Cell Carcinoma

Cited by 3 publications

References 38 publications

Human Dendritic Cells: Their Heterogeneity and Clinical Application Potential in Cancer Immunotherapy

Human Dendritic Cells: Their Heterogeneity and Clinical Application Potential in Cancer Immunotherapy

Metabolic Pathways in Kidney Cancer: Current Therapies and Future Directions

Bioinformatics profiling integrating a four immune-related long non-coding RNAs signature as a prognostic model for papillary renal cell carcinoma

Contact Info

Product

Resources

About